ITPKA

Across TCGA pan-cancer cohorts, ITPKA Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ITPKA data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ITPKA Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ITPKA expression acts as an unfavorable survival marker.

LIHC, STAD, and LUSC are the cancer types where ITPKA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.081	0.543	.006	18	view →
STAD	OS	Median	All	0.220	0.669	.002	12	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ITPKA–LIHC (DFS)

Open the LIHC breakdown →